Literature DB >> 25685761

Role of coronary physiology in the contemporary management of coronary artery disease.

Neil Ruparelia1, Rajesh K Kharbanda1.   

Abstract

Coronary artery disease (CAD) remains the leading cause of death worldwide with approximately 1 in 30 patients with stable CAD experiencing death or acute myocardial infarction each year. The presence and extent of resultant myocardial ischaemia has been shown to confer an increased risk of adverse outcomes. Whilst, optimal medical therapy (OMT) forms the cornerstone of the management of patients with stable CAD, a significant number of patients present with ischaemia refractory to OMT. Historically coronary angiography alone has been used to determine coronary lesion severity in both stable and acute settings. It is increasingly clear that this approach fails to accurately identify the haemodynamic significance of lesions; especially those that are visually "intermediate" in severity. Revascularisation based upon angiographic appearances alone may not reduce coronary events above OMT. Technological advances have enabled the measurement of physiological indices including the fractional flow reserve, the index of microcirculatory resistance and the coronary flow reserve. The integration of these parameters into the routine management of patients presenting to the cardiac catheterization laboratory with CAD represents a critical adjunctive tool in the optimal management of these patients by identifying patients that would most benefit from revascularisation and importantly also highlighting patients that would not gain benefit and therefore reducing the likelihood of adverse outcomes associated with coronary revascularisation. Furthermore, these techniques are applicable to a broad range of patients including those with left main stem disease, proximal coronary disease, diabetes mellitus, previous percutaneous coronary intervention and with previous coronary artery bypass grafting. This review will discuss current concepts relevant to coronary physiology assessment, its role in the management of both stable and acute patients and future applications.

Entities:  

Keywords:  Coronary artery disease; Coronary flow reserve; Coronary physiology; Fractional flow reserve; Ischaemia

Year:  2015        PMID: 25685761      PMCID: PMC4317608          DOI: 10.12998/wjcc.v3.i2.148

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  59 in total

1.  Coronary thermodilution to assess flow reserve: experimental validation.

Authors:  B De Bruyne; N H Pijls; L Smith; M Wievegg; G R Heyndrickx
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

2.  Novel index for invasively assessing the coronary microcirculation.

Authors:  William F Fearon; Leora B Balsam; H M Omar Farouque; Anthony D Caffarelli; Robert C Robbins; Peter J Fitzgerald; Paul G Yock; Alan C Yeung
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

3.  Physiologic assessment of jailed side branch lesions using fractional flow reserve.

Authors:  Bon-Kwon Koo; Hyun-Jai Kang; Tae-Jin Youn; In-Ho Chae; Dong-Joo Choi; Hyo-Soo Kim; Dae-Won Sohn; Byung-Hee Oh; Myoung-Mook Lee; Young-Bae Park; Yun-Shik Choi; Seung-Jae Tahk
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

4.  Comparison of quantitative coronary angiography to visual estimates of lesion severity pre and post PTCA.

Authors:  R K Goldberg; N S Kleiman; S T Minor; J Abukhalil; A E Raizner
Journal:  Am Heart J       Date:  1990-01       Impact factor: 4.749

5.  Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study.

Authors:  Bon-Kwon Koo; Andrejs Erglis; Joon-Hyung Doh; David V Daniels; Sanda Jegere; Hyo-Soo Kim; Allison Dunning; Tony DeFrance; Alexandra Lansky; Jonathan Leipsic; James K Min
Journal:  J Am Coll Cardiol       Date:  2011-11-01       Impact factor: 24.094

6.  Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction.

Authors:  Argyrios Ntalianis; Jan-Willem Sels; Giedrius Davidavicius; Nobuhiro Tanaka; Olivier Muller; Catalina Trana; Emanuele Barbato; Michalis Hamilos; Fabio Mangiacapra; Guy R Heyndrickx; William Wijns; Nico H J Pijls; Bernard De Bruyne
Journal:  JACC Cardiovasc Interv       Date:  2010-12       Impact factor: 11.195

7.  Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy.

Authors:  Rory Hachamovitch; Alan Rozanski; Leslee J Shaw; Gregg W Stone; Louise E J Thomson; John D Friedman; Sean W Hayes; Ishac Cohen; Guido Germano; Daniel S Berman
Journal:  Eur Heart J       Date:  2011-01-21       Impact factor: 29.983

8.  Impact of type 2 diabetes mellitus and glucose control on fractional flow reserve measurements in intermediate grade coronary lesions.

Authors:  Sebastian Reith; Simone Battermann; Martin Hellmich; Nikolaus Marx; Mathias Burgmaier
Journal:  Clin Res Cardiol       Date:  2013-11-22       Impact factor: 5.460

9.  Prognostic value of exercise thallium-201 imaging in patients presenting for evaluation of chest pain.

Authors:  K A Brown; C A Boucher; R D Okada; T E Guiney; J B Newell; H W Strauss; G M Pohost
Journal:  J Am Coll Cardiol       Date:  1983-04       Impact factor: 24.094

10.  Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial.

Authors:  Colin Berry; Jamie Layland; Arvind Sood; Nick P Curzen; Kanarath P Balachandran; Raj Das; Shahid Junejo; Robert A Henderson; Andrew H Briggs; Ian Ford; Keith G Oldroyd
Journal:  Am Heart J       Date:  2013-08-27       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.